What is the treatment for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)

Treatment of BRONJ should follow a stage-based approach, with conservative management as the initial strategy for early stages and surgical intervention reserved for advanced or refractory cases. 1, 2

Staging and Initial Assessment

BRONJ is classified into stages that guide treatment:

  • At-risk patients: No apparent necrotic bone but history of antiresorptive therapy
  • Stage 0: No clinical evidence of necrotic bone but nonspecific findings
  • Stage 1: Exposed/necrotic bone or fistulas; asymptomatic without infection
  • Stage 2: Exposed/necrotic bone or fistulas with infection
  • Stage 3: Exposed/necrotic bone with pain, infection, and complications (pathologic fracture, extraoral fistula, osteolysis extending beyond alveolar bone)

Treatment Approach by Stage

Stage 1 BRONJ

  • Antibacterial mouth rinses (0.12% chlorhexidine)
  • Patient education about oral hygiene
  • Regular follow-up every 8 weeks by dental specialist
  • Removal of mobile bone fragments that irritate soft tissue 1

Stage 2 BRONJ

  • Antibacterial mouth rinses
  • Systemic antibiotics for infection control
  • Pain management with appropriate analgesics
  • Conservative debridement to relieve soft tissue irritation
  • Regular follow-up every 8 weeks 1

Stage 3 BRONJ

  • Antibacterial mouth rinses
  • Systemic antibiotics for infection control
  • Pain management
  • Surgical debridement or resection for long-term palliation
  • Evaluation of removed bone fragments to rule out malignancy 1, 2

Medication Management

  • For patients on bisphosphonates: Discontinuing bisphosphonates at BRONJ diagnosis is unlikely to affect outcomes due to their long half-life 1
  • For patients on denosumab: Temporary discontinuation may potentially enhance BRONJ resolution due to shorter half-life, but must be weighed against risk of skeletal-related events 1
  • Decision to continue or discontinue bone-modifying agents should be made in consultation between the treating physician, patient, and oral health provider 1

Surgical Approaches

  • Conservative approach: Preferred for early stages

    • Removal of superficial necrotic bone
    • Debridement of loose sequestra without exposing uninvolved bone 1, 3
  • Aggressive surgical approach: Reserved for:

    • Stage 3 disease
    • Cases with well-defined sequestrum
    • Refractory cases not responding to conservative treatment 1, 3

Adjunctive Therapies

Several adjunctive therapies have been investigated:

  • Low-Level Laser Therapy (LLLT): May stimulate cell proliferation and soft tissue healing 4
  • Ozone therapy: May stimulate cell proliferation during and after oral surgery 4
  • Hyperbaric oxygen therapy: Benefits remain unclear, but may be helpful in combination with conventional therapy 4

Multidisciplinary Management

  • Regular communication between dental specialist and oncologist about lesion status (resolved, improving, stable, or progressive) 1
  • Collaboration between oral surgeons, oncologists, dentists, and oral medicine specialists 2

Common Pitfalls to Avoid

  1. Aggressive surgical intervention for asymptomatic cases: Conservative management is preferred initially 2
  2. Poor communication between specialists: Regular updates between dental specialists and oncologists are crucial 1, 2
  3. Ignoring modifiable risk factors: Address factors such as smoking, diabetes, and poor oral hygiene 2
  4. Inadequate follow-up: Regular monitoring every 8 weeks is recommended until healing occurs 1, 2
  5. Elective dental procedures in patients with established BRONJ: These may result in additional areas of exposed necrotic bone 1

Prevention Strategies

  • Comprehensive oral evaluation before starting antiresorptive therapy
  • Maintenance of good oral hygiene
  • Regular dental follow-up
  • Avoidance of elective dental procedures during active therapy with bone-modifying agents 2

The management of BRONJ remains challenging, but a stage-based approach with appropriate conservative or surgical interventions based on disease severity offers the best outcomes for patients.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Osteonecrosis of the Jaw Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Surgical management of bisphosphonate induced osteonecrosis of the jaws.

International journal of oral and maxillofacial surgery, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.